Psychedelics

Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.

The Seattle City Council voted yesterday to decriminalize the use, possession, and home cultivation of psilocybin, making it the largest U.S. city so far to enact such reforms.

California’s attorney general last week approved language for an upcoming psychedelic decriminalization ballot initiative.

Cannabis use among college students reached its highest levels in 35 years in 2020, according to the National Institute on Drug Abuse, while alcohol use decreased by 6%.

The DEA last week called for a significant increase in the production of cannabis and psilocybin for the purposes of federal research and clinical trials.

Yale University researchers found that a single dose of psilocybin increases the growth of neural connections which are reduced by chronic stress and depression.

The California Assembly Public Safety Committee passed the Senate-approved psychedelic decriminalization bill on Tuesday.

Lately, CBD brands have started adding adaptogens—plants and mushrooms with healing properties—into their products. Unfortunately, they rarely attribute these ancient medicines to their historical and cultural context.

Goodness Growth Inc. said it will research the effect of “naturally derived” psychedelics on a variety of psychological disorders.

The California Senate has approved a bill to legalize the possession of psychedelics including LSD, MDMA, psilocybin mushrooms, mescaline, and others.

Cannabis entrepreneur and former heavyweight boxing champ Mike Tyson recently said that psilocybin helped him through depression and thoughts of suicide. He is an early investor in Wesana, a Canadian psychedelics-focused wellness company.

Texas lawmakers approved legislation over the weekend to study the effectiveness of psychedelics in treating PTSD among veterans and to reduce possession penalties for cannabis concentrates.

“No one alive is responsible for what happened hundreds or thousands of years ago, but we are part of a continuum.” – Zoe Helene

Dr. Markus Roggen is the founder of Complex Biotech Discovery Ventures, a private research center for cannabis science and collaborator for academic research.

A proposal in Maine is seeking to legalize psilocybin mushroom therapy for anyone aged 21 or older.

The California Senate Public Safety Committee has advanced a psychedelics decriminalization measure.

Researchers at the Imperial College London say that any psychological benefits of microdosing LSD — which are frequently described, at least anecdotally — are likely caused by the placebo effect.

A Missouri lawmaker has proposed expanding the state’s Right to Try law to include psychedelic substances such as psilocybin, MDMA, LSD, mescaline, ibogaine, and DMT.

As an entrepreneur, Michael “Zappy” Zapolin is known as a pioneer in the domain name industry. As a filmmaker, he has emerged as a powerful advocate for the legalization and normalization of psychedelics.

New Jersey Gov. Phil Murphy has signed legislation reducing the penalties for the possession of psilocybin mushrooms from a third-degree crime to a disorderly person offense.

The UK has approved trials to assess the safety — and eventually efficacy — of DMT as a potential treatment for depression.

Lawmakers in New Jersey’s Assembly Judiciary Committee have advanced a bill that would lower possession penalties for psilocybin mushrooms from a potential 5-year prison sentence to a maximum $1,000 fine and six months in jail.

A recent study found that psilocybin therapy offered “more than four times greater” relief than traditional antidepressant medications.